Achillion Appoints CSO
This article was originally published in Scrip
Achillion Pharmaceuticals has appointed Joel Barrish chief scientific officer and executive vice president – effective Jan. 4, 2016. Barrish has over 30 years' experience in the pharmaceutical industry and most recently was vice president and head of discovery chemistry at Bristol-Myers Squibb (BMS). He has also co-authored more than 120 peer-reviewed publications.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.